Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefits and serious safety risks.
The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.
Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.
India makes many of the world’s drugs, but treatments for rare diseases like spinal muscular atrophy are imported and prohibitively costly. In desperation, parents are […]
The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.
If the preliminary decision is finalized this spring, it would restrict coverage to patients in randomized clinical trials.
If the preliminary decision is finalized this spring, it would restrict coverage to patients in randomized clinical trials.
If the preliminary decision is finalized this spring, it would sharply limit the number of patients who use the expensive drug.
Medicare officials are trying to determine whether to cover Aduhelm, which the F.D.A. approved despite unclear evidence that it helps patients.
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for […]
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for […]
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for […]
A group of Alzheimer’s experts and health advocates called on the F.D.A. to withdraw its approval of the drug, the latest of several setbacks for […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many […]
The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.
The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.
The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.
The drug, Aduhelm, has been mired in controversy since it was in approved in the United States in June.
The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue […]
The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue […]
The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.
The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.
The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.
For an increasingly important set of drugs, Medicare has been driving up prices. It knows how to do better.
For an increasingly important set of drugs, Medicare has been driving up prices. It knows how to do better.
The drug from Biogen, called Aduhelm, is expected to generate billions in sales. It could also strain Medicare’s budget within a few years.
The drug from Biogen, called Aduhelm, is expected to generate billions in sales. It could also strain Medicare’s budget within a few years.
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
The major medical center’s rejection of the new Alzheimer’s drug is one of the starkest signs of concern over its effectiveness.
The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules.
The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. Now it recommends that the drug be given only to those with mild symptoms.
The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild […]
Even those who supported the F.D.A.’s approval of the controversial new drug said authorizing it for anyone with Alzheimer’s disease was much too broad.
The Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” for Medicare.
The Alzheimer’s treatment will cost $56,000 per patient, and millions may use it. The result: “crazy numbers” for Medicare.
The F.D.A.’s approval of the Alzheimer’s drug aducanumab is inexplicable.
The F.D.A.’s approval of the Alzheimer’s drug aducanumab is inexplicable.
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some experts say there’s […]
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say […]
Aducanumab is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say there’s not […]
If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say […]
If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say […]
If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say […]
A February conference by the drug company Biogen was initially thought to have infected 99 people. By the end of October, it was feared that […]
A February conference by the drug company Biogen was initially thought to have infected 99 people. By the end of October, it was feared that […]
Copyright © 2024 | WordPress Theme by MH Themes